Penn Medicine Provider
Hematology
Selina M. Luger, MD
she/her/hers
4.9
(390)
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 4th Floor West

About me

  • Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: McGill University
  • Residency: Presbyterian University Hospital
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating
4.9

390 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

May 2025
5.0
5.0
i'm very impressed with the way dr. luger dealt with me.
May 2025
5.0
5.0
provider was easy to talk to, understood my medical issues
May 2025
5.0
5.0
she is always friendly and interested in how she may improve my condition
May 2025
5.0
5.0
we have a lot of faith and trust in dr. luger.

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Luger is a Penn Medicine physician.

Qualifications and experience

My research

Chow RD, Velu P, Deihimi S, Belman JP, Youn A, Shah N, Luger SM, Carroll MP, Morrissette JJ, Bowman RL. Persistent post-remission clonal hematopoiesis shapes the relapse trajectories of acute myeloid leukemia , Blood Adv: 2025


Jillella AP, Lee SJ, Altman JK, Luger SM, Tallman MS, Foran JM, Bradshaw D, Law LY, Bryan LJ, Abou Zahr A, Begna KH, Perl AE, Vadakara JJL, Qamar R, Bergan RC, Fisch MJ, Carlos RC, Wagner LI, Kota VK, Litzow MR. Academic Community Partnership in Acute Promyelocytic Leukemia and Early MortalityThe ECOG-ACRIN EA9131 Trial , JAMA Oncol.: 2025


Wang X, Gimotty PA, Matthews AH, Mamtani R, Luger SM, Hexner EO, Babushok DV, McCurdy SR, Frey NV, Bruno XJ, Gill S, Martin ME, Paralkar VR, Maillard I, Porter DL, Loren AW, Perl AE, Pratz KW, Getz KD, Lai C. Evolving racial/ethnic disparities in AML survival in the novel therapy era , Blood Adv, 9: 2025,533-544


Rowe, M., Babushok, D., Carroll, M., Carulli, A., Frey, N., Gill, S., Hexner, E., Hirsh, R., Hossain, N., Lai, C., Loren, A., Luger, S., Maillard, I., McCurdy, S., Matthews, A., Martin, M.E., Paralkar, V.R., Perl, A., Porter, D., Pratz, K., Stadtmauer, E. and Bruno, X.J. Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen , Eur J Haematol: 2025


Rowe M, Babushok D, Carroll M, Carulli A, Frey N, Gill S, Hexner E, Hirsh R, Hossain N, Lai C, Loren A, Luger S, Maillard I, McCurdy S, Matthews A, Martin ME, Paralkar VR, Perl A, Porter D, Pratz K, Stadtmauer E, Bruno XJ. Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen , Eur J Haematol: 2024


Niedersuess-Beke D, Mayrhofer K, Krauter J, Schnabel S, Gampenrieder SP, Miechowiecki J, Kiesl D, Luger F, Pfuner J, Wiesinger C, Vallet S, Andalibi H, Vais D, Banner A, Stoiber F, Spielgelberg J, Barth D, Bauernhofer T, Aufderklamm S, Weibrecht S, Mühlmann J, Mayer M, Hilbe W, Boulmé F, Klinglmair G, Heintel D, Shariat SF, Pichler M, Pichler R. Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre Study , Clin Genitourin Cancer: 2024


Bijal Shah MD, Ryan J. Mattison MD, Ramzi Abboud MD, Peter Abdelmessieh DO, MSc, Ibrahim Aldoss MD, Patrick W. Burke MD, Daniel J. DeAngelo MD, PhD, Shira Dinner MD, Amir T. Fathi MD, Jordan Gauthier MD, MSc, Michael Haddadin MD, Nitin Jain MD, Brian Jonas MD, PhD, Suzanne Kirby MD, Michaela Liedtke MD, Mark Litzow MD, Aaron Logan MD, PhD, Meixiao Long MD, PhD, Selina Luger MD, James K. Mangan MD, PhD, Stephanie Massaro MD, MPH, William May MD, Olalekan Oluwole MD, Jae Park MD, Amanda Przespolewski DO, Sravanti Rangaraju MD, Caner Saygin MD, Marc Schwartz MD, Paul Shami MD, Benjamin Tomlinson MD, Jonathan Webster MD, Ajibola Awotiwon MBBS, MSc, and Katie Stehman MMS, PA-C Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology , J Natl Compr Canc Netw, 22(8): 2024


Kimura S, Park CS, Montefiori LE, Iacobucci I, Pölönen P, Gao Q, Arnold ED, Attarbaschi A, Brown A, Buldini B, Caldwell KJ, Chang Y, Chen C, Cheng C, Cheng Z, Choi J, Conter V, Crews KR, de Groot-Kruseman HA, Deguchi T, Eguchi M, Muhle HE, Elitzur S, Escherich G, Freeman BB 3rd, Gu Z, Han K, Horibe K, Imamura T, Jeha S, Kato M, Chiew KH, Khan T, Kicinski M, Köhrer S, Kornblau SM, Kotecha RS, Li CK, Liu YC, Locatelli F, Luger SM, Paietta EM, Manabe A, Marquart HV, Masetti R, Maybury M, Mazilier P, Meijerink JPP, Mitchell S, Miyamura T, Moore AS, Oshima K, Pawinska-Wasikowska K, Pieters R, Prater MS, Pruett-Miller SM, Pui CH, Qu C, Reiterova M, Reyes N, Roberts KG, Rowe JM, Sato A, Schmiegelow K, Schrappe M, Shen S, Skoczeń S, Spinelli O, Stary J, Svaton M, Takagi M, Takita J, Tang Y, Teachey DT, Thomas PG, Tomizawa D, Trka J, Varotto E, Vincent TL, Yang JJ, Yeoh AEJ, Zhou Y, Zimmermann M, Inaba H, Mullighan CG. Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk , Cancer Discov: 2024


Badar T, Luger SM, Litzow MR Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia , Blood: 2024


Bhagwat AS, Torres L, Shestova O, Shestov M, Mellors PW, Fisher HR, Farooki SN, Frost BF, Loken MR, Gaymon AL, Frazee D, Rogal W, Frey N, Hexner EO, Luger SM, Loren AW, Martin ME, McCurdy SR, Perl AE, Stadtmauer EA, Brogdon JL, Fraietta JA, Hwang WT, Siegel DL, Plesa G, Aplenc R, Porter DL, June CH, Gill SI. Cytokine-mediated CAR T therapy resistance in AML , Nat Med: 2024